The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.
Multiple myeloma treatments are rapidly evolving beyond traditional options, with personalized sequencing strategies being tested across all disease stages.
This review covers the rapidly evolving immunotherapy landscape for multiple myeloma including CAR-T, bispecific antibodies, and belantamab mafodotin. Novel constructs and sequencing strategies are being tested across all treatment lines.
What the study was
- Study design
- Review
- Population
- Multiple myeloma patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical Lymphoma, Myeloma & Leukemia
Why it surfaced
Comprehensive review from major myeloma centers covering the full immunotherapy landscape. Highly relevant but review format.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.